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Abstract
Background: An important component of the World Health Organization’s comprehensive trachoma elimination strategy is
the provision of repeated annual mass azithromycin distributions, which are directed at reducing the burden of ocular
chlamydia. Knowledge of characteristics associated with infection after mass antibiotic treatments could allow trachoma
programs to focus resources to those most likely to be infected with ocular chlamydia.
Methodology/Principal Findings: We monitored 12 communities in rural Ethiopia that had received 3 annual mass
azithromycin treatments as part of a cluster-randomized trial for trachoma. One year after the third treatment, a random
sample of children from each village received conjunctival examination for follicular trachomatous inflammation (TF) and
intense trachomatous inflammation (TI), conjunctival swabbing for chlamydial RNA and DNA, and a household survey. The
primary outcome for this study was RNA evidence of ocular chlamydia, which we detected in 41 of 573 swabbed children
(7.2%, 95%CI 2.7–17.8). In multivariate mixed effects logistic regression models, ocular chlamydial RNA was significantly
associated with ocular discharge (OR 2.82, 95%CI 1.07–7.42), missing the most recent mass azithromycin treatment (OR 2.49,
95%CI 1.02–6.05), having a sibling with ocular chlamydia (OR 4.44, 95%CI 1.60–12.29), and above-median community
population (OR 7.81, 95%CI 1.56–39.09). Ocular chlamydial infection was also independently associated with TF (OR 3.42,
95%CI 1.56–7.49) and TI (OR 5.39, 95%CI 2.43–11.98).
Conclusions/Significance: In areas with highly prevalent trachoma treated with multiple rounds of mass azithromycin,
trachoma programs could consider continuing mass azithromycin treatments in households that have missed prior mass
antibiotic treatments, in households with clinically active trachoma, and in larger communities.
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Introduction
As part of the SAFE strategy (Surgery for trichiasis, Antibiotics,
Facial hygiene promotion, and Environmental improvements), the
World Health Organization recommends repeated annual mass
antibiotic distributions for trachoma, usually with oral azithromy-
cin, followed by reassessment after at least 3 years of SAFE [1]. In
areas with highly prevalent trachoma, three treatments are unlikely
to be sufficient to eliminate the causative agent, Chlamydia trachomatis
[2,3]. In these areas with highly prevalent disease, re-infection
rapidly occurs, even after ocular chlamydia has been brought to
verylowlevels with repeatedmassazithromycintreatments[4].The
source of re-infection is not entirely clear. It is possible that
untreated neighboring communities provide the source of infection,
and that travel to or visitorsfromthese untreated communities helps
spread infection [5]. Alternatively, it is possible that a reservoir of
infection remains in a treated community after mass azithromycin
treatments, either because of incomplete antibiotic coverage, or
inefficacy of the antibiotic in certain individuals.
It would be helpful for trachoma programs to identify factors
associated with being infected with ocular chlamydia after
repeated mass azithromycin treatments. Trachoma programs
could direct more resources to households with such factors, or
could try to improve the status of these factors, in an effort to
reduce any reservoirs of chlamydial infection after mass treat-
ments. In this study, we performed trachoma monitoring and
household surveys for 12 communities in Ethiopia that had been
treated with 3 annual mass azithromycin treatments, to assess
which factors are associated with ocular chlamydia after repeated
mass antibiotic treatments.
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Ethics Statement
This study was approved by the Committee for Human
Research at the University of California, San Francisco; the
Institutional Review Board at Emory University; and the
Ethiopian Science and Technology Commission. The guardians
of all study participants gave verbal consent in Amharic; we
obtained verbal consent due to the high level of illiteracy in this
region. Verbal consent was approved by the institutional review
boards, and documented on the field data sheets.
Study Design
We performed a cross-sectional study of 12 communities in
Goncha Siso Enese woreda, Amhara Region, Ethiopia to determine
risk factors for ocular chlamydia infection after mass azithromycin
treatments. The 12 communities had been treated with 3 annual
mass azithromycin treatments as part of a cluster-randomized
clinical trial for trachoma (clinicaltrials.gov #NCT00322972)
[6,7]. During the trial, we performed an annual population census,
followed by a mass azithromycin distribution to all persons aged 1
year and older (single dose of oral azithromycin; 1 g for adults,
20 mg/kg for children). Antibiotic distributors documented
whether each individual on the census had received a dose of
azithromycin.
Trachoma Monitoring
In May 2009 (1 year after the third mass azithromycin
treatment), we performed monitoring for ocular chlamydia and
clinically active trachoma. We chose a random sample of 50
children aged 0–9 years from each of the 12 communities, using a
population census that had been performed for the trial 6 months
earlier. We examined the upper right tarsal conjunctiva of each
child, grading for follicular trachomatous inflammation (TF) and
intense trachomatous inflammation (TI) according to the World
Health Organization simplified grading scale [8]. Graders were
trained at the beginning of the study visit, and only allowed to
grade if they achieved sufficient agreement (kappa$0.6) with a
consensus grade from 3 experienced trachoma graders (BA, BDG,
TML) regarding the presence of clinically active trachoma (TF
and/or TI) on a set of 50 conjunctival photographs. Kappas for
clinically active trachoma for the 8 graders in this study ranged
from 0.66 to 0.88. We collected 2 swabs of the upper right tarsal
conjunctiva: first, a Dacron swab, and then, a swab from the
APTIMA-CT Unisex Swab Specimen Collection Kit (Gen-Probe,
Inc., San Diego, CA), which was stored in transport media from
the same kit. Swabs were transported to the University of
California, San Francisco, where the Dacron swabs were
processed for chlamydial DNA using AMPLICOR (Roche
Diagnostics, Indianapolis, IN), and the APTIMA swabs were
processed for chlamydial RNA using APTIMA-CT. In each case,
swabs were analyzed as pools of 5 swabs, with individual testing of
any positive pools.
Household Survey
Using the census records, we identified the households of
examined children. Trained local health workers and nurses
conducted a survey of each identified household in the local
language, Amharic. Surveys were performed between 3 and 21
days following the trachoma monitoring. The intended survey
respondent was the head of the household or spouse. If either of
these persons were not at home, the survey team returned to the
household at a different time. If after three visits the head of
household or spouse could still not be located, a neighbor was
requested to respond to the survey. The survey questions were
developed in conjunction with local health workers and nurses,
and consisted of questions regarding socioeconomic status, use of
antibiotics, availability of latrines and water, and travel. In
addition, all children in the household who were present at the
time of the survey were examined for ocular discharge (discharge
on the eyelashes or eyelids), nasal discharge (discharge on nares,
cheeks, or lips), and flies on the face (presence of 1 or more flies on
the face during the 3-second period of time after all flies had been
shooed away).
Statistical Methods
The primary outcome in this study was RNA evidence of
chlamydial infection, chosen because this is the most sensitive test
for chlamydia currently available [9,10]. We performed univariate
mixed effects logistic regression with the presence of chlamydial
RNA as the outcome, and community as a random effect. Any risk
factors significantly associated with chlamydial infection at p,0.05
were included in a multivariate mixed effects logistic regression
model, and a backwards stepwise selection process was used until
all risk factors in the model were significant at p,0.05. We did not
include TF or TI as predictors in multivariate models since in
communities with hyperendemic trachoma, these clinical signs are
most likely a result of chlamydial infection, as opposed to a risk
factor for infection. As a sensitivity analysis, we performed similar
analyses but included household nested in community as a random
effect. As secondary outcomes, we also assessed risk factors for the
presence of ocular chlamydia DNA, and clinically active
trachoma, defined as TF and/or TI. In the case that the risk
factor perfectly predicted the outcome, penalized maximum
likelihood regression using Firth’s method was used [11]. For
any particular analysis, observations with missing data for the
outcome or risk factor(s) were omitted. The sample size was based
on the underlying clinical trial, which assessed 50 children per
community. Analyses were performed with Stata 10 (Statacorp,
College Station, TX).
Author Summary
Trachoma, which is the leading infectious cause of
blindness worldwide, is caused by repeated ocular
infection with Chlamydia trachomatis. Treatment for
trachoma includes mass azithromycin treatments to the
entire community. The World Health Organization recom-
mends at least 3 rounds of annual mass antibiotic
distributions in areas with trachoma, with further mass
treatments based on the prevalence of trachoma. Howev-
er, there are other options for communities that have
received several rounds of treatment. For example,
programs could continue antibiotic treatments only in
those households most likely to have infected individuals.
In this study, we performed trachoma monitoring on
children from 12 Ethiopian communities one year after a
third mass azithromycin treatment, and conducted a
household survey at the same time. We found that
children were more likely to be infected with ocular
chlamydia if they had ocular inflammatory signs or ocular
discharge, or if they had missed the preceding antibiotic
treatment, had an infected sibling, or came from a larger
community. These risk factors suggest that after mass
azithromycin treatments, trachoma programs could con-
sider continuing antibiotic distributions to households that
have missed prior antibiotic distributions, in households
with children who have the clinical signs of trachoma, and
in larger communities.
Post-Treatment Risk Factors for Ocular Chlamydia
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The 12 communities had a median population of 285 (IQR
212–354). As reported previously, the median prevalence of DNA
evidence of ocular chlamydial infection before treatment was 45%
(IQR 33–54) and the median prevalence of clinically active
trachoma (TF/TI) before treatment was 68% (IQR 55–85) [6]. All
12 communities had received 3 annual mass azithromycin
treatments, with antibiotic coverage in children under 10 years
of age averaging 80.9% (613.3%) at the first treatment, 92.1%
(65.0%) at the second treatment, and 87.3% (611.8%) at the
third treatment [6]. We performed trachoma monitoring 1 year
after the third mass azithromycin treatment. We examined 583
children under 10 years of age, representing 370 households from
12 communities [7]. We were able to complete a household survey
for 575 monitored children, who lived in 364 different households.
We could not locate an adult respondent for the remaining 8
children, who lived in 7 different households from 3 of the
communities.
As shown in Table 1, interviews were conducted primarily with
heads of household (43.0%) or spouse (39.8%), although we did
accept responses from neighbors or other community members if
heads of household were not at home (17.2%). Heads of household
were overwhelmingly male (92.4%), farmers (99.7%), Christian
(100%), and without formal education (85.9%). Households were
generally characterized by poor access to latrines (28.8% of
households had a usable latrine) but good access to water (80.7%
of households were within 30 minutes from water). Most
households attended market and religious services at least weekly
(64.2% and 92.7%, respectively).
Of children who underwent trachoma monitoring and a
household survey, chlamydial RNA was detected in 41/573
children (7.2%, 95%CI 2.7–17.8), chlamydial DNA in 25/575
children (4.4%, 95%CI 1.7–10.6%), and clinically active trachoma
in 247/571 children (43.3%, 34.8–52.1%). TF and TI were
independently associated with ocular chlamydia (Table 2). We
calculated the predictive values of clinically active trachoma for
chlamydial infection at the household level. Of the 200 households
in which at least 1 examined child was noted to have TF and/or TI,
28 had at least 1 child with evidence of chlamydial RNA (i.e.,
household-level positive predictive value 14.0%, 95% CI 6.0–
29.3%). In comparison, there were 164 households in which no
examined children had either TF or TI, and in 157 of these, no
examined child tested positive for chlamydial RNA (i.e., household-
level negative predictive value 95.7%, 95%CI 84.2–99.0%).
In total, the 364 households were comprised of 2,079 persons,
including 863 children under 10 years of age. Non-programmatic
antibiotic use during the preceding 3 months was reported for 123
persons of all ages (5.9%, 95%CI 3.9–8.9%), and 36 children
under 10 years of age (4.2% of children, 95%CI 2.9–6.0%). Most
persons took a single course of antibiotics, though 11/123 (8.9%,
95%CI 4.0–19.0%) had two courses. Of the 134 antibiotic courses
for which a treatment indication was reported, 28 were taken for a
respiratory infection, 23 for fever, 18 for diarrhea, 8 for intestinal
worms, and 57 for other indications.
The travel patterns of surveyed households are shown in
Tables 3 and 4. In general, adults traveled more commonly than
children. For household members who traveled, the total amount
of time spent away per month was bimodal, with 48.5% of the
1,129 travelers away for 4–8 days, and 25.7% away for 18–22
days. The vast majority of visitors stayed for short amounts of time;
93.9% of the 262 visitors stayed at the household for 3 days or less.
Table 5 shows the results of univariate analyses for the primary
outcome (chlamydial RNA) as well as the secondary outcomes
Table 1. Characteristics of 364 households surveyed one year
after a third mass azithromycin treatment.
Household Characteristic Number* Proportion (95% CI)
Survey respondent
Head 150/349 43.0% (33.1–53.5%)
Spouse 139/349 39.8% (31.7–48.6%)
Neighbor 54/349 15.5% (9.8–23.6%)
Other 6/349 1.7% (0.4–8.0%)
Head of household
Male Gender 314/340 92.4% (88.0–95.2%)
Christian Religion 357/357 100% (99.0–100%)
Occupation
Farmer 358/359 99.7% (97.6–99.9%)
Health Extension Worker 1/359 0.3% (0.03–2.4%)
Education
0 years 104/355 29.30% (17.8–44.3%)
Non-formal education{ 201/355 56.6% (41.7–70.5%)
2–10 years 50/355 14.1% (10.4–18.8%)
Development
Distance to water
,30 minutes 284/352 80.7% (59.1–92.4%)
30–60 minutes 42/352 11.9% (5.7–23.5%)
.1 hour 26/352 7.4% (1.4–31.5%)
Latrine at household
Yes, usable 104/361 28.8% (18.3–42.3%)
Yes, but unusable 23/361 6.4% (3.3–12.1%)
No 234/361 64.8% (52.2–75.7%)
Electricity in household 0/352 0% (0–1.0%)
Antibiotic use
Any antibiotic use in past 3
months
99/364 27.2% (20.1–35.7%)
Travel by any member of
household
Currently 176/364 48.4% (38.0–58.8%)
In past month 360/364 98.9% (97.2–99.6%)
.14 days in past month 170/364 46.7% (31.2–62.9%)
Market visits per month
1–3 129/360 35.8% (24.1–49.5%)
4 205/360 56.9% (42.2–70.6%)
5–10 26/360 7.2% (4.2–12.2%)
Church visits per month
1–3 26/356 7.3% (4.1–12.7%)
4 247/356 69.4% (54.8–80.9%)
5–8 55/356 15.5% (7.4–29.5%)
9–30 28/356 7.9% (4.3–14.1%)
Household visitors
Currently 15/364 4.1% (2.3–7.3%)
In past month 110/364 30.2% (19.8–43.3%)
*Denominators less than 364 indicate missing data.
{Refers to a government-sponsored illiteracy campaign.
doi:10.1371/journal.pntd.0001441.t001
Post-Treatment Risk Factors for Ocular Chlamydia
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children who received both trachoma monitoring and a household
survey. Because having an infected sibling depended on whether a
sibling had been selected for trachoma monitoring, we also
performed an analysis restricted only to those 375 children who
had a sibling monitored at the study visit; chlamydial RNA was
still associated with having an infected sibling in this analysis (OR
7.44, 95%CI 2.25–24.56).
In multivariate models (Table 6), chlamydial RNA retained an
association with ocular discharge (OR 2.82, 95%CI 1.07–7.42),
missing the most recent mass azithromycin treatment (OR 2.49,
95%CI 1.02–6.05), having a sibling with ocular chlamydia (OR
4.44, 95%CI 1.60–12.29), and community population above the
median of 285 (OR 7.81, 95%CI 1.56–39.09). Analysis of the
secondary outcomes largely supported the results of the primary
chlamydial RNA outcome (Tables 5 and 6). As a sensitivity
analysis, we performed mixed effects logistic regression models
with household nested in community as a random effect. The
results of these analyses were similar to those shown in Table 5 for
chlamydial RNA and TF/TI, but the chlamydial DNA data did
not support this model (data not shown).
Discussion
We showed that after 3 repeated mass azithromycin treatments,
the factors most strongly predictive of ocular chlamydial RNA
were ocular discharge, missing the previous mass azithromycin
treatment, having a sibling infected with ocular chlamydia, and
living in a larger community. Even after 3 mass treatments, the
clinical signs of trachoma were strongly associated with chlamydial
infection. These findings were confirmed with analyses using
ocular chlamydial DNA as the outcome, and were robust in
models that accounted for community and household clustering.
Few studies have assessed for risk factors of ocular chlamydial
infection before or after mass azithromycin treatments. Studies
conducted before mass treatments have not shown consistent
associations, though various studies have suggested the importance
of unclean faces, age, household fly density, infected siblings, and
absence of a latrine [5,12,13]. The few studies conducted after
mass azithromycin treatments have generally found that missing a
previous mass azithromycin treatment and younger age are
associated with chlamydial infection, though individual studies
have also implicated the absence of a latrine, travel, and the
number of infected and untreated children per household
[5,14,15]. Previous studies have assessed for DNA evidence of
ocular chlamydial infection. In contrast, our primary outcome was
ocular chlamydial RNA—the most sensitive test for chlamydia
currently available [9,10].
The multivariate analysis revealed several risk factors for
chlamydial RNA after repeated mass treatments. The association
between missing the previous mass azithromycin treatment and
ocular chlamydial infection confirms the importance of the
Antibiotic component of the SAFE strategy. The association
between ocular discharge and chlamydial infection seems to
indicate that unclean faces are an important risk factor for
infection even after mass treatments [16]. However, it is also
possible that ocular discharge is not on the causative pathway for
ocular chlamydial infection, but is simply a result of being infected.
The association between above-median community population
and ocular chlamydia could indicate that chlamydial transmission
is more likely in crowded communities, or could simply reflect the
difficulty for chlamydial infection to fade away in larger
communities [17]. This result should be interpreted with caution,
since the population variable was based on only 12 villages. It is
important to note that although we used multivariate analyses, the
Table 2. Association between clinical signs of trachoma and
ocular chlamydial infection after mass azithromycin
treatments.
OR (95%Confidence Interval)*
Clinical Sign Proportion (No.) RNA DNA
MODEL 1{
TF only 26.8% (153/571) 1.93 (0.73–5.14) 8.13 (1.61–40.9)
TI only 8.9% (51/571) 2.13 (0.58–7.82) 8.67 (1.31–57.3)
TF+TI 7.5% (43/571) 20.4 (6.93–60.3) 88.9 (15.7–502)
Normal 56.7% (324/571) Reference Reference
MODEL 2{
TF 34.3% (196/571) 3.42 (1.56–7.49) 9.18 (2.90–29.03)
TI 16.5% (94/571) 5.39 (2.43–11.98) 10.22 (3.59–29.11)
TF=follicular trachomatous inflammation; TI=intense trachomatous
inflammation; RNA=chlamydial rRNA; DNA=chlamydial DNA.
*Multivariate mixed effects logistic regression with either chlamydial RNA or
DNA as the outcome, and community as a random effect.
{Clinical signs of trachoma treated as a single categorical variable, with the
absence of TF or TI (i.e., normal exam) as the reference; Wald p-value for
categorical variable ,0.0001 for each outcome.
{Clinical signs of trachoma treated as separate dichotomous variables.
doi:10.1371/journal.pntd.0001441.t002
Table 3. Travel by household members and visits from outside the community.
Households Children , 10 years Persons $ 10 years
% (95%CI) No./Total % (95%CI) No./Total % (95%CI) No./Total
Household Travelers
On survey day 48.4% (38.0–58.8) 176/364 4.8% (1.8–12.0%) 41/863 24.5% (19.2–30.8) 298/1216
In past month 98.9% (97.2–99.6) 360/364 14.3% (8.0–24.2%) 123/863 82.7% (76.7–87.5) 1006/1216
Household Visitors
On survey day 4.1% (2.3–7.3%) 15/364 N/A 0* N/A 19*
In past month 30.2% (19.8–43.3%) 110/364 N/A 0* N/A 262*
*Number of visitors to all 364 households; denominator unknown.
N/A=not applicable.
doi:10.1371/journal.pntd.0001441.t003
Post-Treatment Risk Factors for Ocular Chlamydia
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Consistent with previous reports, we were unable to show that
accessibility to water or latrine status were associated with either
ocular chlamydia or clinical trachoma after mass antibiotics
[5,12,13]. Although a previous study did find that lack of a latrine
was associated with ocular chlamydial infection after mass
azithromycin treatment, that study found that the relationship
became weaker over time, and by 12 months after the mass
treatment (analogous to this study), was no longer significant [5]. It
is possible that our inability to detect an association with the E
components of the SAFE strategy in the current study is a function
of an insufficient sample size, or misclassification during the
survey, or an insufficient follow-up period. Nonetheless, across
several studies, missing mass antibiotic treatments does seem to be
the most important predictor of chlamydial infection and
trachoma, at least in the short term. Further investigation into
the role of missed azithromycin treatments, including ways to
improve coverage of mass treatments, is warranted.
Our results provide evidence that after repeated mass
azithromycin treatments, trachoma programs may be able to
target antibiotic treatments to those most likely to be infected. For
example, TF and TI were independently associated with ocular
chlamydial RNA after 3 mass treatments—not surprising, since
infection causes the clinical signs of trachoma. Moreover, having
an infected sibling was significantly associated with ocular
chlamydial infection. This is consistent with previous reports that
have shown that ocular chlamydial infection clusters by household
[18,19,20]. Taken together, these results suggest that treating the
households of children with clinically active trachoma, as the
WHO has suggested in the past, may be a reasonable way to target
those individuals most likely to be infected after repeated rounds of
mass azithromycin have already been distributed [21]. In this
study, treatment targeted to households in which any child was
observed to have clinically active trachoma would have resulted in
antibiotic distributions to only 55% (200/364) of households, but
still would have covered 80% (28/35) of households with ocular
chlamydia. However, the feasibility and cost-effectiveness of such a
strategy remains to be determined, since targeting households with
clinically active trachoma would require examinations of all
children in the community. A simpler strategy might be to
continue mass azithromycin treatments in areas with highly
prevalent trachoma. In fact, the WHO now recommends 5 rounds
of mass treatment for areas with hyperendemic trachoma, a
strategy that would likely benefit the communities in this study
[22].
As a secondary outcome, we assessed risk factors for having a
positive chlamydial DNA test. These results confirmed the risk
factors found for the primary RNA outcome, and also suggested
that travel outside the community, or hosting a visitor from outside
the community, may be associated with ocular chlamydial
infection. Travel to and from outside communities could re-
introduce ocular chlamydia into a treated household. Other
studies have similarly found that travel could be an important risk
factor for trachoma [5,23]. Trachoma programs with knowledge
of major migration episodes may choose to wait until after the
travel has occurred before scheduling a mass distribution of
azithromycin, or treat a large enough area in order to mitigate this
potential problem. In addition, given that most travel was done
over short periods of time, trachoma programs may increase
coverage to most travelers simply by returning to households with
absent members in several days time.
We also assessed for risk factors of the clinical signs of trachoma,
TF and TI, as a secondary outcome. Most previous studies that
have assessed for risk factors for clinically active trachoma have
been conducted before mass azithromycin treatments have been
initiated. In these studies, several risk factors have consistently
been associated with clinically active trachoma, including
indicators of poor face hygiene such as nasal discharge and the
presence of flies [13,24,25,26,27,28,29], household fly density
[12,25,28,30,31], distance to water [27,32,33,34,35,36], absence
of a latrine [32,34,37], and number of children per household
[27,37,38,39]. Fewer studies have reported risk factors for
clinically active trachoma after mass antibiotic treatments. These
studies have generally demonstrated that younger age, lack of
latrines, unclean faces, and missed mass azithromycin treatments
are associated with clinically active trachoma [14,40,41]. In this
study, conducted after 3 annual mass azithromycin distributions,
clinically active trachoma was associated with younger age and
ocular discharge, two commonly reported risk factors. In addition,
active trachoma was associated with having a visitor in the past
month, and male gender. The significance of the association
between TF/TI and male gender is unclear, as ocular chlamydial
infection was not more common among boys. Past studies have
more frequently demonstrated an association between clinically
active trachoma and female gender [12,26,34,42], though several
studies have noted more clinically active trachoma among boys
[38,40]. The generalizability of this finding is uncertain, and may
simply reflect the specific sample of individuals in this study.
In both univariate and multivariate analyses, the results for the
primary RNA outcome were almost always confirmed by the
results for the secondary DNA outcome, but often differed from
the results of the TF/TI outcome. This likely occurred because the
RNA-based and DNA-based tests are related tests, in that both are
testing for genetic evidence of chlamydia. The clinical examina-
tion, on the other hand, is a test for conjunctival inflammation,
Table 4. Travel destination and time spent at destination.
Children aged , 10 years Persons aged $ 10 years
Destination % of Travelers (No.) Days per Month, mean % of Travelers (No.) Days per Month, mean
Market 8.9% (11/123) 2.6461.29 70.0% (704/1006) 2.9661.28
Church 7.3% (9/123) 5.4465.73 66.3% (667/1006) 4.6163.63
School 69.1% (85/123) 18.663.68 25.3% (254/1006) 19.263.79
Town 5.7% (7/123) 2.4362.15 4.4% (44/1006) 4.0567.18
Other 20.1% (27/123) 2.6764.61 13.3% (134/1006) 4.1167.63
Numbers do not sum to 100% since some household members traveled to multiple destinations.
doi:10.1371/journal.pntd.0001441.t004
Post-Treatment Risk Factors for Ocular Chlamydia
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Odds Ratio (95% Confidence Interval)*
Factor
Proportion (No.)
or Mean ±SD RNA DNA TF/TI
Individual demographics
Age, years 5.262.7 0.95 (0.84–1.07) 0.89 (0.77–1.04) 0.84 (0.79–0.90)
Male gender 51.9% (298/574) 0.91 (0.45–1.83) 1.03 (0.44–2.38) 1.50 (1.06–2.12)
Individual examination
Ocular discharge 15.8% (91/575) 3.15 (1.27–7.80) 3.79 (1.40–10.26) 3.51 (2.10–5.86)
Nasal discharge 53.6% (308/575) 1.38 (0.64–2.98) 0.90 (0.36–2.28) 1.46 (1.00–2.12)
Flies on face 15.0% (86/575) 0.92 (0.33–2.53) 1.18 (0.37–3.80) 1.59 (0.97–2.61)
Individual antibiotic use
No mass azithromycin 1 year prior 12.1% (65/536) 3.07 (1.30–7.26) 4.76 (1.83–12.36) 1.88 (1.08–3.28)
No antibiotics in past 3 months 95.5% (549/575) 1.46 (0.17–12.70) 2.58 (0.15–43.49)
{ 0.62 (0.28–1.40)
Individual travel
Currently 4.5% (26/575) 1.41 (0.27–7.45) 2.40 (0.45–12.75) 0.73 (0.31–1.75)
.7 days in past month 9.7% (56/575) 1.59 (0.51–4.89) 1.42 (0.37–5.52) 0.83 (0.45–1.50)
.14 days in past month 9.0% (52/575) 1.79 (0.56–5.74) 1.62 (0.40–6.50) 0.72 (0.38–1.36)
Household Sociodemographics
Number in household 5.961.8 0.99 (0.80–1.23) 0.95 (0.73–1.23) 0.91 (0.83–1.01)
Presence of sibling ,5 years 56.0% (322/575) 2.03 (0.97–4.27) 1.79 (0.73–4.39) 0.90 (0.64–1.28)
Number of siblings ,5 years 0.760.7 1.67 (1.02–2.72) 1.61 (0.90–2.88) 0.96 (0.75–1.23)
Distance to water $30 minutes 21.1% (117/575) 0.48 (0.09–2.65) 0.33 (0.03–3.17) 0.61 (0.36–1.02)
No usable latrine 72.0% (412/572) 1.35 (0.57–3.20) 3.37 (0.93–12.15) 1.20 (0.80–1.80)
No education, head of household 85.8% (483/563) 1.96 (0.64–6.01) 2.48 (0.55–11.14) 1.40 (0.84–2.34)
Survey completed by neighbor/other 16.2% (93/575) 0.96 (0.41–2.24) 1.75 (0.69–4.44) 1.26 (0.79–2.02)
Sibling factors
Sibling with chlamydial RNA 4.2% (24/575) 5.05 (1.86–13.73) 13.82 (4.32–44.18) 1.92 (0.78–4.71)
Sibling with TF/TI 33.0% (190/575) 1.30 (0.64–2.64) 1.95 (0.84–4.53) 1.32 (0.92–1.90)
No mass azithromycin to sibling 1 y prior 22.4% (129/575) 2.21 (1.04–4.69) 2.43 (0.99–5.97) 0.76 (0.49–1.19)
Antibiotic use by anyone in household
No antibiotics in past 3 months 71.8% (413/575) 1.09 (0.48–2.46) 1.46 (0.51–4.16) 0.92 (0.62–1.36)
Travel by anyone in household
Currently 48.0% (276/575) 1.72 (0.83–3.57) 3.44 (1.30–9.14) 1.14 (0.79–1.63)
.7 days in past month 81.9% (471/575) 1.76 (0.57–5.47) 11.94 (0.72–197.7)
{ 0.94 (0.59–1.50)
.14 days in past month 47.3% (272/575) 1.01 (0.47–2.15) 0.88 (0.35–2.19) 0.81 (0.55–1.19)
Market .4 times per month 7.4% (42/571) 1.25 (0.38–4.10) 1.62 (0.43–6.16) 1.52 (0.79–2.94)
Church .4 times per month 24.3% (137/564) 1.07 (0.44–2.57) 0.38 (0.10–1.43) 0.82 (0.53–1.26)
Household visitors
Currently 4.4% (25/575) 1.79 (0.33–9.63) 3.15 (0.58–17.10) 1.12 (0.48–2.64)
In past month 31.7% (182/575) 1.86 (0.88–3.93) 3.35 (1.31–8.52) 1.50 (1.01–2.21)
Number of visitors in past month 0.761.3 1.22 (0.95–1.57) 1.45 (1.09–1.94) 1.07 (0.93–1.24)
Village factors
Population (100s of persons) 3.1361.15 2.00 (0.89–4.52) 1.94 (0.83–4.53) 1.07 (0.82–1.40)
Population .285 persons 51.5% (296/575) 9.42 (1.64–53.94) 12.03 (1.99–72.81) 1.47 (0.82–2.66)
Pre-treatment prevalence CT .45% 50.8% (292/575) 0.78 (0.09–6.77) 0.87 (0.11–6.80) 1.42 (0.78–2.58)
Pre-treatment prevalence TF/TI .68% 47.3% (272/575) 2.62 (0.36–19.04) 1.69 (0.23–12.20) 1.05 (0.56–1.97)
1
st round antibiotic coverage ,90% 83.7% (481/575) 3.18 (0.16–63.90) 4.05 (0.19–87.55) 0.97 (0.42–2.26)
2
nd round antibiotic coverage ,90% 30.8% (177/575) 0.83 (0.09–7.96) 0.57 (0.06–5.18) 1.05 (0.53–2.05)
3
rd round antibiotic coverage ,90% 48.0% (276/575) 8.08 (1.46–44.87) 8.02 (1.60–40.25) 1.68 (0.96–2.93)
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roughly 43% of children had TF/TI in this study, whereas only
7% had RNA evidence of chlamydial infection, consistent with
other reports that have shown that the clinical signs of trachoma
persist for many months after chlamydial infection has been
cleared [46,47]. Nonetheless, there were 2 factors that were
associated with all 3 outcomes: ocular discharge and missing the
previous mass azithromycin treatment. The role of ocular
discharge as a risk factor is unclear, since it may simply be a
result of infection. However, that missing a previous mass
azithromycin treatment was associated with all 3 outcomes
suggests that this is an important trachoma risk factor, and
suggests trachoma programs should make efforts to enhance
antibiotic coverage.
This study has several limitations. We chose a random sample of
children from each community, and therefore did not assess the
clinical or infectious status of all children in surveyed households.
This sampling strategy limited our sample size, which did not
allow us to assess for the presence of weaker associations. Due to
the observational study design, we are unable to comment on
antecedent-consequent relationships. Other limitations of surveys
apply, such as the potential for recall bias and misclassification
errors.
In conclusion, we showed that after 3 annual mass azithromycin
treatments in a region of Ethiopia with highly prevalent trachoma,
ocular chlamydial RNA was associated with missing the previous
mass antibiotic treatment, ocular discharge, larger community
size, having an infected sibling, and the clinical signs of trachoma
(TF and/or TI). These findings suggest that (1) maximizing
antibiotic coverage and promoting face washing are important
goals for trachoma programs; (2) larger communities may require
more prolonged treatment compared to smaller communities; and
(3) after repeated mass azithromycin treatments, trachoma
programs could consider antibiotic distribution strategies that
target children with clinically active trachoma and their siblings.
Further research into the factors associated with chlamydial
infection after repeated mass azithromycin distributions will be
helpful to guide trachoma program activities after mass azithro-
mycin distributions have begun.
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